As we discussed in a recent blog, the House of Commons Science and Technology Committee's ambitious and wide-reaching inquiry into genomics and genome editing is examining the role that genomic technologies can play in health, agriculture and the environment. The PHG Foundation's written response to the inquiry was one of many sent, and the variety of organisations and individuals responding resul...
The PHG Foundation has submitted a response to the Nuffield Council on Bioethics consultation on genome editing.
The need for faster access to useful scientific innovations to improve healthcare – making science work for health - has long been a central message of the PHG Foundation, and forms the basis of our current innovation manifesto.
Clinical oncology is undergoing major change as precision medicine informs molecular diagnosis and therapeutics, based on the genomic profiles of the individual patient’s tumours. The presence of genomic targets can be critical to efficacy in treatment, and cancer therapies are increasingly directed to biologically relevant targets based on the molecular profile of tumour cells. For example, the...
The UK Bioindustry Association (BIA) has set out a ten-year vision of its ambitions for the national life sciences sector.
The changing regulatory landscape in Europe
A new report sets out a pathway for the UK to build on scientific excellence in regenerative medicine and accelerate transfer into clinical use.
The PHG Foundation recently held a dissemination event for the Realising Genomics in Clinical Practice report. This was the culmination of a two-year project that sought to inform the optimal clinical implementation of expanded next generation sequencing (NGS) gene panels, whole exome sequencing and ultimately whole genome sequencing.
Personal genomics company 23andMe has taken the first step back towards direct-to-consumer (DTC) genetic testing in the US with regulatory approval granted for a single condition by the Food and Drug Administration (FDA).
Multinational DNA sequencing company Illumina and four major US centres for cancer research have established a new Actionable Genome Consortium (AGC) with the purpose of defining the principles and content of the ‘cancer actionable genome’.
Mitochondrial diseases are a complex and incompletely understood group of conditions arising from genetic defects that impair the function of the mitochondria, the cellular energy-producing structures. These include mutations in the small amounts of extra-nuclear mitochondrial DNA (mtDNA).
The Medical Research Council (MRC) has released a new document examining the UK’s molecular pathology capacity, and in particular changes required to create a robust system that will support increasing need for diagnostic testing.